The Scientist

» CAR T cells

Most Recent

image: New Insights to Improve CAR T Cells’ Safety

New Insights to Improve CAR T Cells’ Safety

By Vicki Brower | June 5, 2018

Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice.

0 Comments

image: World’s Largest Cell and Gene Therapy Plant Opens

World’s Largest Cell and Gene Therapy Plant Opens

By Catherine Offord | April 11, 2018

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.

0 Comments

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

0 Comments

More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 

0 Comments

image: Antiviral Immunotherapy Comes of Age

Antiviral Immunotherapy Comes of Age

By Lucas Laursen | December 4, 2017

T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 

0 Comments

image: New CAR T-Cell Therapy Shows Promise in Trial for Leukemia

New CAR T-Cell Therapy Shows Promise in Trial for Leukemia

By Katarina Zimmer | November 21, 2017

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

0 Comments

A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro. 

1 Comment

image: FDA Approves Second CAR T-Cell Therapy

FDA Approves Second CAR T-Cell Therapy

By Ashley P. Taylor | October 19, 2017

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

0 Comments

image: First CAR T-Cell Therapy Approved in U.S.

First CAR T-Cell Therapy Approved in U.S.

By Shawna Williams | August 30, 2017

The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

1 Comment

image: Gilead to Pay Nearly $12B for CAR T-Cell Company

Gilead to Pay Nearly $12B for CAR T-Cell Company

By Jef Akst | August 28, 2017

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

0 Comments

Popular Now

  1. Dartmouth Professor Investigated for Sexual Misconduct Retires
  2. Two University of Rochester Professors Resign in Protest
  3. Theranos Leaders Indicted For Fraud
    The Nutshell Theranos Leaders Indicted For Fraud

    Federal prosecutors filed criminal charges that allege the company’s promise to revolutionize blood testing swindled investors out of hundreds of millions of dollars and put patients in danger.

  4. Laxative Causes Long-Term Changes to Mouse Microbiome